← All candidates
Four insider buys in the last year — $60.9K in all.
22 filings on record.
APREAprea Therapeutics, Inc.
NasdaqCM · Healthcare · $9.74M
$0.7540
-3.46% · Sep 15
Four insider buys in the last year — $60.9K in all.
Nothing in the last fortnight.
Price · 1Y · daily● 4 buys◆ 11 8-K
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
Reverse-split 1×. When a company does a reverse split, the chart rewrites its old prices to look far bigger than they really were — so the high early prices here aren't what APRE ever actually traded at. The drop is real, but those huge old numbers aren't.
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$9.74M
Float
7.9M
63% public
Short % float
Pro
Price / profit
—
not yet profitable
Price / future profit
—
Price / sales
1879.3
The buyers
▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions
President/CEO
Gilad Oren
Bought $25.0K on Jan 30 — 28,100 sh @ $0.8900, held direct, 7.5% of their stake.
First Form 4 on file
Director
Duey Marc
Bought $25.0K on Dec 10 — 21,459 sh @ $1.17, held direct, 8.4% of their stake.
First Form 4 on file
SrVP/CFO/Prin Fin & Acct Ofcr
Hamill John P.
Bought $5.8K on Dec 10 — 5,000 sh @ $1.17, held direct, 18% of their stake.
First Form 4 on file
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
1 filingnewest first
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
15 more transactions on Pro →Context
Wall St
$4.30 avg target
+470.3% vs today · 4 analysts · consensus Strong Buy
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
3 of 4 quarters beat
Q1 '26−$0.22 act+$0.01
Q4 '25−$0.32 act+$0.04
Q3 '25−$0.47 act−$0.37
Q2 '25−$0.53 act+$0.18
The file stays open
22 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice